Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLNO Soleno Therapeutics

Market Closed 01-16 16:00:00 EST

42.48

+0.53

+1.26%

盘后43.70

+1.22+2.87%

19:53 EST

High43.70	Low41.34	Vol1.17M
Open41.95	D1 Closing41.95	Amplitude5.63%
Mkt Cap2.28B	Tradable Cap1.91B	Total Shares53.71M
T/O49.84M	T/O Rate2.61%	Tradable Shares44.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLNO","market":"US","secType":"STK","nameCN":"Soleno Therapeutics","latestPrice":42.48,"timestamp":1768597200000,"preClose":41.95,"halted":0,"volume":1169594,"hourTrading":{"tag":"盘后","latestPrice":43.7,"preClose":42.48,"latestTime":"19:53 EST","volume":43131,"amount":1834289.665,"timestamp":1768611198056},"delay":0,"floatShares":44870900,"shares":53710025,"eps":-1.75,"marketStatus":"Market Closed","change":0.53,"latestTime":"01-16 16:00:00 EST","open":41.95,"high":43.7,"low":41.34,"amount":49842084.56684,"amplitude":0.056257,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.75,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":41.95,"preHourTrading":{"tag":"盘前","latestPrice":41.96,"preClose":41.95,"latestTime":"09:29 EST","volume":341,"amount":14338.44302,"timestamp":1768573799999},"postHourTrading":{"tag":"盘后","latestPrice":43.7,"preClose":42.48,"latestTime":"19:53 EST","volume":43131,"amount":1834289.665,"timestamp":1768611198056},"volumeRatio":0.549849,"impliedVol":0.7774,"impliedVolPercentile":0.5857},"requestUrl":"/m/hq/s/SLNO/wiki","defaultTab":"wiki","newsList":[{"id":"1130640668","title":"Stock Track | Soleno Therapeutics Plummets 5.06% Intraday After Baird Cuts Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1130640668","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130640668?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:18","pubTimestamp":1768317517,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) saw its shares drop sharply by 5.06% during Tuesday's intraday trading session. The decline followed a negative adjustment by Baird, which lowered its target price for the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SLNO"],"gpt_icon":0},{"id":"2603976638","title":"Cantor Fitzgerald Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603976638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603976638?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:37","pubTimestamp":1768315054,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Soleno Therapeutics today and set a price target of $123.00. Kluska covers the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-soleno-therapeutics-slno-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-soleno-therapeutics-slno-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2603168143","title":"Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2603168143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603168143?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:46","pubTimestamp":1768308417,"startTime":"0","endTime":"0","summary":"In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Soleno Therapeutics, with a price target of $106.00. Accordin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/soleno-therapeutics-slno-receives-a-buy-from-wells-fargo-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/soleno-therapeutics-slno-receives-a-buy-from-wells-fargo-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1267930573.SGD","LU0683600562.USD","IE00B7SZLL34.SGD","LU0477156953.USD","LU1363072403.SGD","LU0128525689.USD","LU2361044865.SGD","LU0314106906.USD","LU2461242641.AUD","LU0251142724.SGD","BK4207","SLNO","LU0175139822.USD","BK4585","LU0310799852.SGD","IE0002270589.USD","LU0256863811.USD","LU0310800379.SGD","LU0208291251.USD","BK4504","LU2361045086.USD","LU0320765489.SGD","LU1201861249.SGD","BK4501","LU0149725797.USD","LU1506573853.SGD","BK4588","IE00B19Z3581.USD","LU0052756011.USD","LU0130517989.USD","LU0128525929.USD","LU2361044949.HKD","LU0310800965.SGD","BK4559","LU0048573561.USD","LU0971096721.USD","LU0742534661.SGD","LU0130102774.USD","LU0289960550.SGD","LU1280957306.USD","LU2236285917.USD","LU0787776722.HKD","LU0980610538.SGD","LU1668664300.SGD","LU0251131958.USD","LU0868494617.USD","LU1035773651.USD","LU0417517546.SGD","LU0942090050.USD","LU1894683348.USD"],"gpt_icon":0},{"id":"2603576317","title":"Soleno Therapeutics: Sustained U.S. Vykat XR Outperformance and European Upside Support Buy Rating and $100 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576317","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603576317?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:36","pubTimestamp":1768271770,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Kate Dellorusso maintained a Buy rating on Soleno Therapeutics yesterday and set a price target of $100.00. Kate Dellorusso...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/soleno-therapeutics-sustained-u-s-vykat-xr-outperformance-and-european-upside-support-buy-rating-and-100-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/soleno-therapeutics-sustained-u-s-vykat-xr-outperformance-and-european-upside-support-buy-rating-and-100-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2603282965","title":"Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2603282965","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603282965?lang=en_us&edition=fundamental","pubTime":"2026-01-13 02:55","pubTimestamp":1768244125,"startTime":"0","endTime":"0","summary":"Wolfe Research lowered the firm’s price target on Soleno Therapeutics (SLNO) to $60 from $75 and keeps an Outperform rating on the shares. The firm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-price-target-lowered-to-60-from-75-at-wolfe-research-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-price-target-lowered-to-60-from-75-at-wolfe-research-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2602241541","title":"BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners","url":"https://stock-news.laohu8.com/highlight/detail?id=2602241541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602241541?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:40","pubTimestamp":1768232404,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver minersEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL6N3YD0S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HL","AWK","JILL","LYRA","AKAM","EPD","BAC","WBD","WMT","URBN","MRNA","SLNO","SNCY","KLAR","MDLN","BIRK","OMF","AGCO","SHAK","AFRM","JBHT","SYF","FERG","SLM","URI","CAT","JCAP","APH","SEZL","CRH","ATRA","VG","CRWD","QXO","ZYME","SRRK","XYZ","AEO","ABNB","ANF","CDE","ALB","CMI","NEM","SCCO"],"gpt_icon":1},{"id":"2602546946","title":"Soleno Therapeutics Reverse Premarket Gains, Last Down 1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602546946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602546946?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:36","pubTimestamp":1768228571,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD1MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"2602351019","title":"Soleno Therapeutics Preliminary Q4 Net Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2602351019","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602351019?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:09","pubTimestamp":1768223399,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics  reported preliminary Q4 net revenue Monday of $90 million to $92 million.Analysts surveyed by FactSet expect $83.3 million.The biotech company also said it has achieved profitability and positive cash flow and reported preliminary cash, cash equivalents and marketable securities of $500 million as of Dec. 31.Shares of the company were up more than 3% in recent Monday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLNO"],"gpt_icon":0},{"id":"2602851417","title":"Soleno Therapeutics Projects 2025 Net Revenue of Up to $191 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851417","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851417?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:03","pubTimestamp":1768219438,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics Inc. has reported select preliminary financial results for the fourth quarter and full year 2025, highlighting significant growth following the U.S. launch of VYKAT XR. The company expects preliminary unaudited full-year 2025 net revenue from U.S. sales of VYKAT XR to range between $189 million and $191 million. Fourth quarter net revenue is projected to be between $90 million and $92 million. Since the launch in the second quarter, Soleno has received 1,250 new patient start forms for VYKAT XR, representing approximately 12.5% of the total U.S. addressable market for the treatment. The company credits the strong performance to the successful launch and rapid market uptake of VYKAT XR, marking a transformational year for Soleno Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL4xxXnt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","SG9999014013.SGD","BK4139","LU0314104364.USD","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","SG9999014021.USD","SLNO","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","BK4588","SG9999014039.USD"],"gpt_icon":0},{"id":"2602851424","title":"Soleno Therapeutics Inc  Q4 REV View $81.7 Mln -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851424","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851424?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA9KBZYW:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2602514517","title":"Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514517","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514517?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219212,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA9KBZYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"2602514108","title":"Soleno Therapeutics Inc - 2025 Net Revenue From US Sales of Vykat Xr Since Q2 Expected Between $189 Mln-$191 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514108","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514108?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA9KBZYW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2602251421","title":"Soleno Therapeutics Inc - Achieves Profitability and Positive Cash Flow","url":"https://stock-news.laohu8.com/highlight/detail?id=2602251421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602251421?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219212,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA9KBZYW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2602051420","title":"Soleno Therapeutics Inc - Vykat Xr Discontinuation Rate Due to Adverse Events About 12%, as of Q4 End","url":"https://stock-news.laohu8.com/highlight/detail?id=2602051420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602051420?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA9KBZYW:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"2602377036","title":"Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602377036","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602377036?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:28","pubTimestamp":1767968898,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics recently reported that pivotal Phase 3 results for VYKAT XR in Prader-Willi syndrome were published in the Journal of Clinical Endocrinology and Metabolism, reinforcing the clinical basis for its FDA approval as the first treatment for hyperphagia in this population.\nThe publication arrives amid short seller criticism of VYKAT XR’s safety and pricing, putting independently reviewed efficacy and safety data at the center of the debate.\nWith these peer-reviewed Phase 3...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/will-peerreviewed-vykat-xr-data-calm-safety-debate-and-chang","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/will-peerreviewed-vykat-xr-data-calm-safety-debate-and-chang","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2601818318","title":"Soleno Therapeutics Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2601818318","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601818318?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:01","pubTimestamp":1767618118,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics Inc. has announced the publication of results from a pivotal clinical study evaluating VYKAT XR  in the treatment of hyperphagia in individuals with Prader-Willi syndrome . The results, now published in the Journal of Clinical Endocrinology and Metabolism, are from a 16-week randomized, double-blind, placebo-controlled withdrawal period study involving children and adults aged four years and older. The study demonstrated that participants who transitioned to placebo experienced a significant worsening of hyperphagia compared to those who remained on VYKAT XR. These findings contributed to the U.S. FDA approval of VYKAT XR as the first and only treatment for hyperphagia in PWS. The results have been publicly presented through this peer-reviewed publication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL2tKWnq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4585","BK4139","SG9999014005.SGD","BK4112","SG9999014013.SGD","SLNO","NDAQ","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2593497970","title":"BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2593497970","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593497970?lang=en_us&edition=fundamental","pubTime":"2025-12-23 20:25","pubTimestamp":1766492737,"startTime":"0","endTime":"0","summary":"BUZZ-Oppenheimer starts Aardvarkwith 'outperform' on differentiated obesity franchise** Brokerage Oppenheimer initiates coverage on Aardvark Therapeutics AARD.O with an \"outperform\" rating and a $35 P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT0JS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","AARD","BK4139"],"gpt_icon":0},{"id":"2588046610","title":"Soleno Therapeutics (SLNO) Valuation Check After Wolfe’s Bullish Call Challenges Short-Seller Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046610","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046610?lang=en_us&edition=fundamental","pubTime":"2025-12-04 15:17","pubTimestamp":1764832634,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) is back on traders’ radar after Wolfe Research launched coverage with a bullish stance, pushing back against short seller driven worries about its lead drug and recent launch stumbles.\nSee our latest analysis for Soleno Therapeutics.\nThe upbeat Wolfe call has helped steady sentiment after a bruising few months. The 1 day share price return of 5.41% has partially offset a 30 day share price return of minus 22.74%, while the three year total shareholder return of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/soleno-therapeutics-slno-valuation-check-after-wolfes-bullis","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/soleno-therapeutics-slno-valuation-check-after-wolfes-bullis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","SLNO","BK4139","BK4112"],"gpt_icon":1},{"id":"2588702125","title":"Press Release: Soleno Therapeutics Announces the Passing of Board Member William G. Harris","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702125","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588702125?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:05","pubTimestamp":1764795900,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Dec. 03, 2025  -- Soleno Therapeutics, Inc.  , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. \"Bill\" Harris, who served as a valued member of Soleno's Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Committee.This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms su","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","SLNO","BK4099","BK4555","03160","BK4588","TM","BK4585","BK4139"],"gpt_icon":0},{"id":"2588408580","title":"How Does Wolfe Research’s Support Shape Soleno Therapeutics’ (SLNO) Credibility Amid Heightened Scrutiny?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588408580","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588408580?lang=en_us&edition=fundamental","pubTime":"2025-12-02 09:12","pubTimestamp":1764637966,"startTime":"0","endTime":"0","summary":"Wolfe Research recently initiated coverage on Soleno Therapeutics, providing a positive outlook for ViCAT XR after concerns were raised over its safety and commercial prospects.\nThis coverage comes in the wake of both a short seller report and ongoing legal investigations, reflecting heightened scrutiny and contrasting expert perspectives for investors.\nWe’ll explore how Wolfe Research’s assessment of ViCAT XR’s insurance access and patient growth prospects shapes the company’s investment...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/how-does-wolfe-researchs-support-shape-soleno-therapeutics-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/how-does-wolfe-researchs-support-shape-soleno-therapeutics-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLNO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.soleno.life","stockEarnings":[{"period":"1week","weight":-0.0121},{"period":"1month","weight":-0.1375},{"period":"3month","weight":-0.3512},{"period":"6month","weight":-0.5128},{"period":"1year","weight":-0.0763},{"period":"ytd","weight":-0.0825}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.033174},{"month":2,"riseRate":0.272727,"avgChangeRate":0.254619},{"month":3,"riseRate":0.636364,"avgChangeRate":0.007758},{"month":4,"riseRate":0.454545,"avgChangeRate":0.050237},{"month":5,"riseRate":0.545455,"avgChangeRate":0.074125},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.071619},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.051924},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014863},{"month":9,"riseRate":0.454545,"avgChangeRate":0.409781},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.115533},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.012609},{"month":12,"riseRate":0.333333,"avgChangeRate":0.051862}],"exchange":"NASDAQ","name":"Soleno Therapeutics","nameEN":"Soleno Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Soleno Therapeutics,SLNO,Soleno Therapeutics股票,Soleno Therapeutics股票老虎,Soleno Therapeutics股票老虎国际,Soleno Therapeutics行情,Soleno Therapeutics股票行情,Soleno Therapeutics股价,Soleno Therapeutics股市,Soleno Therapeutics股票价格,Soleno Therapeutics股票交易,Soleno Therapeutics股票购买,Soleno Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction